Nasdaq.comUS
MetaVia Inc. Announces Completion of Last Patient Visit in Phase 1 Study of DA-1726
MetaVia Inc. announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist…